CDXS Stock Analysis: Buy, Sell, or Hold?
CDXS - Codexis, Inc.
$1.74
0.11 (6.75%)
▲
5d:
-0.57%
30d:
+77.55%
90d:
+8.75%
BUY
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 13, 2026
Smart Money Distribution
CDXS is up 18.5% this week, but smart money is buying puts. Top strike: $2 2026-04-17 with 10 OI. Put ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When CDXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CDXS shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CDXS shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CDXS is currently trading at $1.74, which is considered extended relative to its 30-day fair value range of $1.13 to $1.65. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.6) compared to its historical average (16.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CDXS is in a strong uptrend. Immediate support is located at $1.42, while resistance sits at $1.80. The stock is showing strong short-term momentum, up 6.7% recently.
Market Sentiment: CDXS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.58 (+278.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CDXS is in a strong uptrend. Immediate support is located at $1.42, while resistance sits at $1.80. The stock is showing strong short-term momentum, up 6.7% recently.
Market Sentiment: CDXS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.58 (+278.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$1.13 -
$1.65
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range (+5.5% above fair value)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.7%)
- BULLISH: Trading 278.4% below Wall St target ($6.58)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Fair Price Analysis
30-Day Fair Range
$1.13 -
$1.65
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$1.42
Resistance Level
$1.80
Current Trend
Strong Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.58
Wall Street Target
$6.58
(+278.4%)
Revenue Growth (YoY)
81.3%
Profit Margin
-62.5%
PE vs Historical
-4.6 vs 16.6
CHEAP
Share & Embed Analysis
Last updated: April 02, 2026 5:40 AM ET
Data refreshes hourly during market hours. Next update: 6:40 AM
Data refreshes hourly during market hours. Next update: 6:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CDXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Stefan Lutz
SELL
5862 shares
2026-02-24
Alison Moore
SELL
3826 shares
2026-02-06
Georgia Erbez
SELL
3826 shares
2026-02-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 65 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 62 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 59 HOLD |
